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Methods: Between 2003–2006, 2364 nondemented persons underwent computed tomography of the
coronaries, aortic arch, extracranial, and intracranial carotid arteries to quantify atherosclerotic calci-
fication. Participants were followed for incident dementia (n5 90) until April 2012. At baseline and
follow-up participants also underwent a cognitive test battery.
Results: Larger calcification volume in all vessels, except in the coronaries, was associated with a
higher risk of dementia. After adjustment for relevant confounders, extracranial carotid artery calci-
fication remained significantly associated with a higher risk of dementia [hazard ratio per standard
deviation increase in calcification volume: 1.37 (1.05, 1.79)]. Additional analyses for Alzheimer’s
disease only or censoring for stroke showed similar results. Larger calcification volumes were also
associated with cognitive decline.
Conclusions: Atherosclerosis, in particular in the extracranial carotid arteries, is related to a higher
risk of dementia and cognitive decline.
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Dementia, including Alzheimer’s disease, is a devastating
condition with a huge societal impact, both in terms of pa-
tient suffering and financial cost [1,2]. An important
feature of dementia is the long preclinical phase, during
which subtle cognitive deficits develop that can only be
measured using dedicated neuropsychological tests [3].
The underlying etiology of dementia and cognitive decline
is multifactorial and involves different pathologies which
interact and accumulate over the course of years [4]. In addi-
tion to beta-amyloid and tau pathology, the role of vascular
pathology in the etiology of dementia and Alzheimer’s dis-
ease is increasingly being recognized [5,6].thor. Tel.:131-10-70-43930; Fax:131-10-40-89382.
.a.ikram@erasmusmc.nl
nt matter  2015 The Alzheimer’s Association. Published b
16/j.jalz.2014.05.1758Atherosclerosis is highly frequent in the aging population
and is considered the most important hallmark of vascular
pathology [7]. Thus far, most studies have focused on athero-
sclerosis in the carotid bifurcation in relation to dementia [8–
10]. Indeed, both carotid intima-media thickness and carotid
plaques have been associated with dementia, including Alz-
heimer’s disease [8–10].
However, several important questions remain unanswered.
First, atherosclerosis is a systemic disease, but its burden dif-
fers considerably across vessel beds [7,11,12]. It is therefore
conceivable that the contribution of atherosclerosis to
dementia may vary depending on the vessel bed. Such
differential contribution of atherosclerosis in various vessel
beds to disease risk has already been demonstrated for
stroke, and even for mortality [13,14]. Second, the study of
vascular factors in dementia is often complicated by stroke,
which can act as intermediate factor [9,10]. It is thereforey Elsevier Inc. All rights reserved.
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dementia independent from stroke. Finally, given that both
atherosclerosis and dementia develop over the course of
years, it is important to study how atherosclerosis affects
the preclinical phase of dementia, namely the period of
cognitive decline without overt clinical disease.
Disentangling the exact role of atherosclerosis in demen-
tia is important, because this knowledge may then serve as
basis to develop opportunities for therapeutic or preventive
intervention. Against this background, we aimed to study
the relationship of atherosclerosis in the coronary arteries,
aortic arch, extracranial and intracranial internal carotid ar-
teries with incident dementia, including Alzheimer’s disease
and the potential influence of stroke on these associations.
Finally, we focused on the relationship of atherosclerosis
with cognitive decline.2. Methods
2.1. Setting
This study is based on the Rotterdam Study, a prospec-
tive, population-based study aimed at investigating determi-
nants of chronic diseases in the elderly [15]. The original
cohort comprised 7983 participants aged 55 years or older
and was extended in 2000–2001 with 3011 persons. At study
entry and every 3–4 years, all participants are re-examined in
a dedicated research center.
Between 2003 and 2006, all participants visiting the
research center were invited to undergo non-enhanced
computed tomography (CT). Therefore for this study,
2003–2006 is taken as baseline. In total, we scanned 2524
participants (response rate 78%). Both during the 2003–
2006-visit and the following visit in 2008–2012 persons un-
derwent cognitive testing. The cohort was screened for de-
mentia at baseline to exclude persons with prevalent
dementia. From then onwards, the dementia-free cohort
was followed-up for dementia through in-person screening
at the follow-up visit and through continuous monitoring
for dementia via computerized linkage between the study
database and medical records from general practitioners
and the Regional Institute for Outpatient Mental Health
Care, from baseline until April 27, 2012. The Rotterdam
Study has been approved by the medical ethics committee
according to the Population Study Act Rotterdam Study,
executed by the Ministry of Health, Welfare and Sports of
the Netherlands. A written informed consent was obtained
from all participants.
2.2. Sample for analysis
Fig. 1 shows the composition of the study population.
Due to the presence of a pacemaker, coronary stent implan-
tations or image artifacts, 111 examinations from the 2524
were not gradable, leaving a total of 2413 participants with
a complete CT examination. From these, 2364 participants
were at risk for developing dementia (incorrect dementia-screening or prevalent dementia excluded), encompassing
the study population at baseline.
From these 2364 participants, 437 refused a second
cognitive examination or had died during follow-up, 38
were incapable of follow-up visit (e.g. physical limitations),
16 had been institutionalized or moved, 10 could not be
reached, for seven participants the appointment was post-
poned for logistical reasons, and in nine participants the
cognitive assessment was incomplete and could not be
used. This left 1847 participants with data on cognitive
change (Mini-Mental State Examination, MMSE, or at least
one cognitive test).2.3. CT Acquisition and processing
We used a 16-slice (n5 785) or 64-slice (n5 1739) mul-
tidetector CT scanner (Somatom Sensation 16 or 64,
Siemens, Forchheim, Germany) to perform noncontrast
CT-scanning. Using a cardiac scan and a scan that reached
from the aortic arch to the intracranial vasculature (1 cm
above the sella turcica), we scanned the following vessel
beds: the coronary arteries, the aortic arch, the extracranial
carotid arteries, and the intracranial carotid arteries
(Fig. 2). Detailed information regarding imaging parameters
of both scans is described elsewhere [12].
We used dedicated commercially available software
(Syngo Calcium Scoring, Siemens, Germany) to quantify
calcification volume in the coronary arteries, aortic arch,
and extracranial carotid arteries [12]. For calcification in
the intracranial carotid arteries we used a semiautomated
scoring method which is described in detail elsewhere [16].
Briefly, we delineated calcification in the intracranial carotid
arteries manually in every CT slice. Next, we calculated the
volume of intracranial carotid artery calcification by multi-
plying the number of pixels above the threshold of 130
Hounsfield units [17] with the pixel size and slice increment.
The interrater reliability of this method is very good (in-
traclass correlation coefficient, 0.99) [16]. Calcification vol-
umes in each vessel bed are expressed in cubic millimeters.
Correlations between calcification across the four vessel
beds ranged from 0.5 to 0.6 [12,18].2.4. Ascertainment of dementia
We screened participants for dementia at baseline and
follow-up using a three-step protocol [19,20]. The first
screening step consisted of the MMSE and the Geriatric
Mental Schedule (GMS) organic level. If participants were
screen-positive (MMSE , 26 or GMS organic level . 0),
they entered the second step which consisted of the Cam-
bridge Examination for Mental Disorders in the Elderly
[20]. Additionally, persons underwent history taking,
assessment of activities of daily living, informant interview,
retrieval of relevant medical records, and additional
neuropsychological testing. When information on neuroi-
maging was available (38/90 dementia cases; 42%), it was
Fig. 1. Flowchart of the composition of the study sample.
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mation was already obtained through the medical records,
neuropsychological testing was not performed. Third, all re-
maining caseswere discussed in a consensus panel consisting
of research physicians led by an experienced neurologist,
deciding on the final diagnosis in accordance with standard
criteria using the Diagnostic and Statistical Manual of
Mental Disorders, version III, revised (DSM-III-R) criteria
for dementia. If applicable, subtyping of dementia was
done using the National Institute of Neurological and
Communicative Diseases and Stroke-Alzheimer’s Disease
and Related Disorders Association (NINCDS-ADRDA) for
Alzheimer’s disease and National Institute of Neurological
Disorders and Stroke and Association Internationale pour
la Recherche et l’Enseignement en Neurosciences
(NINDS-AIREN) for vascular dementia [21,22].
Additionally, the total cohort was continuously moni-
tored for dementia through computerized linkage between
the study database and medical records from general practi-
tioners and the Regional Institute for Outpatient Mental
Health Care. This was important to identify those persons
that became demented, who did not visit our research center
and therefore were not detected by our dementia screening.
If available, the consensus panel used results from screening
and information obtained by monitoring medical records to
assess a dementia diagnosis. Consequently, in certain cases
(18 out of 90 cases) information from both sources was
used. For the remaining cases, 53 were detected trough
computerized linkage and 19 through return visits.
2.5. Assessment of cognitive function and cognitive
decline
Both at baseline and at a follow-up examination in
2008–2012, participants underwent the MMSE [23]. In addi-
tion, each participant underwent a more extensive neuropsy-
chological test battery which consisted of the following
tests: the Stroop test (reading, color-naming, and interferencesubtask), the Letter-Digit Substitution Task (LDST), a Word-
Fluency test (WFT), and a 15-Word verbal Learning Task
(15-WLT) [24,25]. We calculated decline for MMSE and
each cognitive test by subtracting the test-score at follow-up
from the test-score at baseline for each individual. The differ-
ences for cognitive tests were subsequently standardized (i.e.
Z-scores) to aid the comparison across tests. Z-scores for each
subtask of the Stroop testwere inverted, because higher scores
for these indicate worse performance, whereas higher scores
on the other tests indicate better performance. Finally, we
averaged the Z-scores to yield a measure of global cognition.
2.6. Other measurements in the Rotterdam Study
We collected detailed information on cardiovascular risk
factors by interview, physical examination and blood
sampling [15]. The following cardiovascular risk factors
were measured: obesity, hypertension, diabetes, hypercho-
lesterolemia, low high-density lipoprotein (HDL)-choles-
terol level, and smoking status. Obesity was defined as a
body-mass index  30 kg/m2. Hypertension was defined
as systolic blood pressure 140 mmHg and/or diastolic
blood pressure 90 mmHg and/or the use of blood pressure
lowering medication [26]. Diabetes was defined as fasting
serum glucose levels 7.0 mmol/l and/or the use of antidia-
betic therapy [27]. Hypercholesterolemia was defined as to-
tal cholesterol concentration 6.2 mmol/l and/or the use of
lipid-lowering medication [28]. We defined low HDL-
cholesterol as HDL-cholesterol, 1.0 mmol/l [28]. Smoking
was categorized into never or ever smoked. Level of educa-
tion was assessed by self-report [25]. We performed apolipo-
protein (APOE) - genotyping on coded genomic DNA
samples and coded it positive (carrier of one or two ε4-
alleles) or negative (noncarrier). The definition of stroke
was based on World Health Organization criteria as a syn-
drome of rapidly developing symptoms of cerebral dysfunc-
tion lasting 24 hours or longer or leading to death, with
apparent vascular cause [29,30]. History of stroke was
Fig. 2. Examples of calcification in the four examined vessel beds. Arrows indicate atherosclerotic calcified lesions in: the left coronary artery (upper left), the
aortic arch (upper right), the left and the right extracranial internal carotid arteries (lower left), and the left and right intracranial internal carotid arteries (lower
right).
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reviewing medical records [29]. After enrolment, we contin-
uously monitored participants for incident stroke through
linkage of the study database with files from general practi-
tioners. We also checked nursing home physicians’ files and
files from general practitioners of participants who moved
out of the district. From the 152 stroke-cases in our study,
neuroimaging was available in 101 persons (66 %). When
neuroimaging was not available, strokes were categorized
as “unspecified”, but still considered as an event. Potential
strokes were reviewed by research physicians and verified
by an experienced stroke neurologist [29].
2.7. Statistical analysis
Because calcification volume had a skewed, non-normal
distribution, we used natural log-transformed values and
added 1.0 mm3 to the nontransformed values to deal with
calcium scores of zero [Ln(calcification 1 1.0 mm3)].
We assessed the relationship between calcification vol-
ume in each vessel bed and the risk of dementia using Cox
regression models. In the first model we adjusted for age,
sex and educational level (model 1). In a second model,
we adjusted for cardiovascular risk factors (obesity, hyper-tension, diabetes mellitus, hypercholesterolemia, low
HDL-cholesterol levels, and smoking status) and APOE
ε4-carriership status (model 2). Next, associations between
calcification and dementia were reanalyzed after exclusion
of participants with prevalent stroke at baseline (n 5 78)
or incident stroke during the dementia follow-up (n 5 74).
We used linear regression to study the relationship of
calcification volume with decline in MMSE, global cogni-
tion and the standardized separate neurocognitive tests.
The adjustments we performed were identical to those in
models 1 and 2 used for dementia, with the addition of
time interval between baseline and follow-up as covariate.
Subsequent analyses were performed after exclusion of per-
sons with stroke (n 5 90) and dementia (n 5 42).
IBM SPSS Statistics version 20 (International Business
Machines Corporation, Armonk, NY) was used for statisti-
cal analyses.
3. Results
The baseline characteristics of our study participants are
summarized in Table 1. (Supplementary Table 1 also depicts
the characteristics of the source population, from which the
current sample was derived.) The mean age at baseline was
Table 1
Baseline characteristics of the study population
Sample size 2364
Women 52.3%
Age, yrs 69.4 (6.7)
Highest education attained:
Primary education 10.3%
Low level vocational training 20.8%
Medium level secondary training 17.9%
Medium level vocational to university training 49.1%
Obesity 23.9%
BMI, kg/m2 27.7 (3.9)
Hypertension 73.7%
Systolic blood pressure, mmHg 146.7 (20.1)
Diastolic blood pressure, mmHg 80.3 (10.7)
Diabetes 11.2%
Serum glucose, mmol/L 5.7 (1.3)
Hypercholesterolemia 48.6%
Serum total cholesterol, mmol/L 5.7 (1.0)
Low HDL cholesterol 10.6%
Serum HDL cholesterol, mmol/L 1.4 (0.4)
Smoking, ever 67.5%
APOE ε4-carriers 25.6%
Abbreviations:APOE, apolipoprotein; BMI, bodymass index; HDL, high
density lipoprotein; n, number of cases; N, number of persons at risk; HR,
hazard ratio; CI, confidence interval; SD, standard deviation.
NOTE. Values are means (standard deviation) for continuous variables
and percentages for dichotomous variables.
Table 2
Atherosclerotic calcification and the risk of dementia and Alzheimer’s
disease
Dementia Alzheimer’s disease
n/N 5 90/2364
P
n/N 5 73/2364
PHR (95% CI) HR (95% CI)
Per SD increase in:
Model 1
Coronary calcification 1.10 (0.86; 1.41) .44 1.16 (0.88; 1.53) .31
Aortic arch calcification 1.38 (1.02; 1.86) .04 1.46 (1.04; 2.06) .03
Extracranial carotid
calcification
1.39 (1.09; 1.77) ,.01 1.31 (1.01; 1.72) .05
Intracranial carotid
calcification
1.31 (1.01; 1.70) .05 1.29 (0.96; 1.74) .09
Model 2
Coronary calcification 1.12 (0.85; 1.48) .43 1.17 (0.85; 1.60) .34
Aortic arch calcification 1.27 (0.93; 1.73) .13 1.32 (0.93; 1.89) .12
Extracranial carotid
calcification
1.37 (1.05; 1.79) .02 1.26 (0.94; 1.68) .13
Intracranial carotid
calcification
1.32 (0.98; 1.77) .07 1.22 (0.88; 1.70) .23
Abbreviations: n, number of cases; N, number of persons at risk; HR, haz-
ard ratio; CI, confidence interval; SD, standard deviation.
NOTE. Model 1: Adjusted for age, sex, and level of education. Model 2:
As model 1, additionally adjusted for obesity, hypertension, diabetes melli-
tus, hypercholesterolemia, low HDL-cholesterol levels, smoking status and
APOE ε4-carrier status.
Table 3
Atherosclerotic calcification and the risk of dementia and Alzheimer’s
disease, censored for stroke
Dementia Alzheimer’s disease
n/N 5 77/2212
P
n/N 5 63/2212
PHR (95% CI) HR (95% CI)
Per SD increase in:
Coronary calcification 1.05 (0.80; 1.36) .74 1.09 (0.81; 1.46) .57
Aortic arch calcification 1.34 (0.97; 1.83) .07 1.32 (0.92; 1.88) .13
Extracranial carotid
calcification
1.32 (1.02; 1.71) .04 1.24 (0.94; 1.65) .13
Intracranial carotid
calcification
1.34 (1.01; 1.78) .05 1.28 (0.93; 1.76) .12
Abbreviations: n, number of cases; N, number of persons at risk; HR, haz-
ard ratio; CI, confidence interval; SD, standard deviation.
NOTE. Adjusted for age, sex, and level of education.
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During 13,397 person years of follow-up, 90 participants
developed dementia (incidence rate of 6.7 cases per 1000
person years). Of these, 73 were diagnosed with Alzheimer’s
disease, three with vascular dementia and 14 with other/
undetermined types of dementia. In total, 152 participants
suffered a stroke of whom 13 later developed dementia.
Hence, 77 participants developed dementia without previous
stroke (63 with Alzheimer’s disease). On average, people
declined 0.27 6 2.00 points on the MMSE during a mean
follow-up period of 6.0 6 0.5 years.
We found that larger calcification volumes in the aortic
arch, extracranial carotid arteries and intracranial carotid ar-
teries, but not in the coronary arteries, were related to a
higher risk of dementia (Table 2, model 1). Additional
adjustment for cardiovascular risk factors and APOE ε4
status did slightly attenuate these associations (Table 2,
model 2).We found similar associations for Alzheimer’s dis-
ease (Table 2).
After censoring for stroke, both extracranial and intracra-
nial carotid artery calcification remained statistically signif-
icantly associated with dementia [hazard ratio (HR) per
standard deviation increase in calcification volume: 1.32
(95% confidence interval, CI: 1.02, 1.71) and 1.34 (95%
CI: 1.01, 1.78), respectively]. Effect sizes for the remaining
associations also remained similar, though statistically
nonsignificant (Table 3).
For cognitive decline, we found that calcification in all
vessel beds, including the coronary arteries, was associated
with decline in global cognition and, apart from extracranial
carotid artery calcification, with decline in MMSE (Table 4,model 1). Additional adjustment for cardiovascular risk fac-
tors and APOE ε4 status attenuated most associations, but
the associations of coronary artery calcification with MMSE
and the association of intracranial carotid artery calcification
with MMSE and global cognition remained statistically
significant [MMSE per SD increase—coronary artery
calcification b520.15 (95%CI:20.25,20.05); intracranial
carotid artery calcification b 5 20.12 (95% CI: 20.22,
20.01)] [global cognition per SD increase: intracranial ca-
rotid artery calcification b5 20.03 (95% CI:20.06, 0.00)]
(Table 4, model 2). After censoring for stroke, coronary artery
calcification remained statistically significantly associated
with MMSE [MMSE per SD increase: coronary artery calci-
fication b 5 20.11 (95% CI: 0.21, 20.01)]. Effect sizes for
Table 4
Calcification in different vessel beds and global cognitive decline
Global cognition MMSE
Difference in Z-score (95% CI) P Difference in points (95% CI) P
Per SD increase in:
Model 1
Coronary calcification 20.03 (20.06; 0.00) .03 20.15 (20.25; 20.05) ,.01
Aortic arch calcification 20.03 (20.05; 0.00) .06 20.11 (20.21; 20.01) .03
Extracranial carotid calcification 20.03 (20.06; 0.00) .04 20.07 (20.16; 0.03) .19
Intracranial carotid calcification 20.04 (20.07;20.02) ,.01 20.09 (20.19; 0.00) .06
Model 2
Coronary calcification 20.02 (20.05; 0.01) .13 20.16 (20.27; 20.05) ,.01
Aortic arch calcification 20.01 (20.04; 0.02) .39 20.11 (20.22; 20.01) .03
Extracranial carotid calcification 20.02 (20.05; 0.01) .22 20.07 (20.17; 0.04) .22
Intracranial carotid calcification 20.03 (20.06; 0.00) .03 20.12 (20.22; 20.01) .03
Abbreviations: HDL, high density lipoprotein; CI, confidence interval; SD, standard deviation.
NOTE. Model 1: Adjusted for age, sex, time interval, and level of education. Model 2: As model 1, additionally adjusted for obesity, hypertension, diabetes
mellitus, hypercholesterolemia, low HDL-cholesterol levels, smoking status, and APOE ε4-carrier status.
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icant (Supplementary Table 2). After we excluded all persons
who developed dementia during follow-up, we still found
similar associations of calcification with cognitive decline
(Supplementary Table 2).
Associations of calcification with the separate cognitive
tests are shown in (Tables 5 and 6). We found most promi-
nent associations of calcification volume in the coronary ar-
teries and the intracranial carotid arteries with decline in
scores on the LDST.4. Discussion
In this sample of community-dwelling middle-aged and
elderly persons, we found that atherosclerotic calcification,
in particular in the extracranial carotid arteries, was related
to a higher risk of dementia, including Alzheimer’s disease.
Furthermore, we found atherosclerotic calcification to be
associated with cognitive decline in nondemented persons.Table 5
Calcification in different vessel beds and cognitive decline per single test (Stroop
Stroop reading* Stroop nami
Difference in Z-score
P
Difference i
(95% CI) (95% CI)
Per SD increase in:
Model 1
Coronary calcification 0.01 (20.05; 0.07) .72 0.02 (20.
Aortic arch calcification 20.02 (20.08; 0.03) .38 20.00 (20.
Extracranial carotid calcification 20.01 (20.06; 0.05) .79 20.02 (20.
Intracranial carotid calcification 20.02 (20.07; 0.04) .57 20.02 (20.
Model 2
Coronary calcification 0.02 (20.04; 0.08) .49 0.03 (20.
Aortic arch calcification 20.02 (20.07; 0.04) .60 0.00 (20.
Extracranial carotid calcification 0.02 (20.04; 0.08) .57 20.01 (20.
Intracranial carotid calcification 0.00 (20.05; 0.06) .88 20.02 (20.
Abbreviations: CWI, color word interference; LDST, letter–digit substitution ta
NOTE. Model 1: Adjusted for age, sex, time interval, and level of education. M
mellitus, hypercholesterolemia, low HDL-cholesterol levels, smoking status, and
*Inverted scores; lower scores indicate worse performance.Strengths of our study include the longitudinal
population-based setting, the image-based quantification of
atherosclerosis, and the focus on both cognitive decline and
dementia. Moreover, our close collaborations with general
practitioners in the study area, in combination with the struc-
ture of theDutch health care system allowed us to accomplish
virtually complete follow-up with regard to development of
dementia. The incidence rate of dementia in our sample
was comparable to incidence rates reported in other studies
[20,31].
Several potential limitations should also be addressed.
First, additional adjustment for covariates affected the re-
sults regarding dementia and cognitive decline. Yet, in
most cases the effect estimates remained largely unchanged.
It is possible that addition of multiple covariates to the
model in combination with the relatively small sample
size may have led to less statistical power. Importantly,
this does not necessarily imply that there is no real associa-
tion between atherosclerosis and the outcomes. Second, weTest and LDST)
ng* Stroop CWI* LDST
n Z-score
P
Difference in Z-score
P
Difference in Z-score
P(95% CI) (95% CI)
03; 0.08) .43 20.01 (20.06; 0.05) .79 20.06 (20.12; 20.01) .02
05; 0.05) .97 20.01 (20.07; 0.04) .65 20.06 (20.11; 0.00) .04
07; 0.03) .47 0.01 (20.04; 0.07) .67 20.06 (20.11;20.01) .02
07; 0.04) .54 20.02 (20.07; 0.03) .42 20.05 (20.10; 0.00) .03
03; 0.08) .39 0.01 (20.05; 0.07) .74 20.06 (20.12;20.01) .03
06; 0.05) .94 0.01 (20.05; 0.06) .78 20.05 (20.10; 0.01) .08
06; 0.05) .84 0.04 (20.02; 0.09) .24 20.05 (20.10; 0.01) .10
07; 0.04) .53 20.02 (20.07; 0.04) .58 20.06 (20.11;20.01) .03
sk; CI, confidence interval; SD, standard deviation.
odel 2: As model 1, additionally adjusted for obesity, hypertension, diabetes
APOE ε4-carrier status.
Table 6
Calcification in different vessel beds and cognitive decline per single test (WFT and 15-WLT)
WFT 15-WLT DR 15-WLT IR
Difference in Z-score
P
Difference in Z-score
P
Difference in Z-score
P(95% CI) (95% CI) (95% CI)
Per SD increase in:
Model 1
Coronary calcification 20.03 (20.08; 0.03) .31 20.04 (20.09; 0.02) .24 20.04 (20.10; 0.02) .20
Aortic arch calcification 20.01 (20.06; 0.04) .68 20.02 (20.08; 0.04) .48 20.03 (20.08; 0.03) .38
Extracranial carotid calcification 0.00 (20.05; 0.05) .88 20.07 (20.13;20.02) .01 20.01 (20.06; 0.05) .76
Intracranial carotid calcification 20.06 (20.11;20.01) .03 20.04 (-0.09; 0.02) .18 20.02 (20.08; 0.03) .44
Model 2
Coronary calcification 20.03 (20.08; 0.03) .36 20.03 (20.09; 0.03) .34 20.04 (20.10; 0.02) .20
Aortic arch calcification 0.00 (20.05; 0.06) .93 20.01 (20.07; 0.05) .85 20.02 (20.08; 0.04) .48
Extracranial carotid calcification 0.02 (20.04; 0.07) .55 20.08 (20.14; 20.02) .01 20.02 (20.08; 0.04) .49
Intracranial carotid calcification 20.04 (20.10; 0.01) .10 20.02 (20.08; 0.04) .47 20.02 (20.08; 0.04) .44
Abbreviations: WFT, Word Fluency Task; WLT DR, 15-word learning test delayed recall; WLT IR, 15-word verbal learning test immediate recall; CI, con-
fidence interval; SD, standard deviation.
NOTE. Model 1: Adjusted for age, sex, time interval, and level of education. Model 2: As model 1, additionally adjusted for obesity, hypertension, diabetes
mellitus, hypercholesterolemia, low HDL-cholesterol levels, smoking status, and APOE ε4-carrier status.
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flated our type I error. However, an important consideration
here is that most tests are actually not completely indepen-
dent (e.g. the various cognitive domains are correlated and
calcification in the different vessels is correlated). There-
fore, conventional corrections for multiple testing would
be overconservative [32]. Another consideration is that
calcification is only a part of the atherosclerotic plaque. Us-
ing nonenhanced CT it is not possible to visualize the com-
plete atherosclerotic plaque area and thus potentially
interesting information on additional plaque characteristics,
such as shape, stenosis or ulceration could not be measured.
Nonetheless, strong evidence suggests that CT-based calci-
fication volume provides an adequate reflection of the total
underlying plaque burden [33]. For the assessment of calci-
fication we used two types of multidetector CT-scanners (16
slice and 64 slice CT), which could have influenced the
measurements. However, post-hoc analyses with adjust-
ment for scanner type did not change the results. Next,
due to selective participation of younger and healthier sub-
jects, our results may be underestimating true associations.
We also note that structural neuroimaging was not available
in all participants to aid in the diagnostic process. This could
have led to potential misclassification of vascular dementia
as AD. Yet, we expect this misclassification to be minimal,
given that we always used all clinical information [34].
Finally, we did not have neuropathological confirmation
of dementia.
We found that atherosclerotic calcification in multiple
vessel bedswas related to a higher risk of dementia. Several ex-
planations may underlie this association. First, our findings
could be explained by an intermediary role for stroke. Athero-
sclerosis is a powerful risk factor for stroke [35], and in turn
stroke-patients have an almost twofold increased risk of de-
mentia [6,36]. However, censoring at time of stroke changed
little in our associations of calcification with incidentdementia. A similar absence of an effect of stroke has been
shown for the relationship between carotid intima-media thick-
ness anddementia [9,10].Another point of consideration is that
atherosclerosis in the carotid artery represents the strongest
location of atherosclerosis related to stroke [37,38]. In
contrast, we found associations with dementia for other
vessel beds as well. This also points toward our findings
being independent from stroke. Actually, this suggests that
generalized atherosclerosis, which probably is a better
reflection of one’s vascular status rather than localized
atherosclerosis, is associated with dementia.
A second explanation linking atherosclerosis to dementia
is subclinical small vessel disease [6,39]. Autopsy studies
provide strong evidence that most patients with
Alzheimer’s disease show small vessel disease in their
brain [6]. This includes infarcts, microinfarcts, microbleeds,
demyelinization, and axonal damage [6]. In vivo imaging
studies have shown that MRI-markers of small vessel dis-
ease, e.g. white matter lesions and lacunar infarcts, are asso-
ciated with the risk of dementia [6,40,41]. We have
previously demonstrated that atherosclerotic calcification
in all four vessel beds is strongly associated with these
MRI-markers of subclinical vascular brain disease [18].
Together, this points toward a role for small vessel disease
in the association of atherosclerosis with dementia.
Finally, chronic hypoperfusion may explain the associa-
tion between atherosclerosis and dementia, especially Alz-
heimer’s disease [6]. As a consequence of slowly
progressing structural changes of cerebral vessels due to
atherosclerosis, cerebral perfusion is impaired which could
lead to subclinical vascular brain disease on the one hand,
but may also cause loss of functionality of the blood-brain
barrier. This in turn might allow increased parenchymal
deposition of beta-amyloid protein and/or impaired amyloid
clearance and thereby the formation of amyloid plaques, an
important characteristic of Alzheimer’s disease [5,6,42].
D. Bos et al. / Alzheimer’s & Dementia 11 (2015) 639-647646Research on dementia is very often challenging due to the
possibility of competing risks [9]. In our study competing risk
due tomortalitymight explain the lack of association between
coronary artery calcification and dementia. The coronary ar-
teries are the singlemost important location of atherosclerosis
for risk of cardiac events, including cardiac death [13]. It is
therefore conceivable that persons in our studywith the largest
load of coronary calcification died of competing risks and
therefore did not remain at risk to develop dementia. Indeed,
post-hoc analyses revealed that especially coronary artery
calcification was associated with mortality.
By investigating cognitive decline in addition to the
endpoint of dementia, we managed to circumvent competing
risks to a certain extent. We found that atherosclerotic calcifi-
cation in all locations, including the coronary arteries, was
associated with cognitive decline. Moreover, when we
repeated our analyses after excluding persons who converted
to dementia during follow-up, we found that the results re-
mained unchanged. This implies that our resultswere unlikely
to be driven by preclinical dementia, but that atherosclerosis
already plays an important role in the early stages of cognitive
deterioration, presumably already years before the possible
conversion to clinical dementia. Whereas our study had a
follow-up period of 6 years, others found carotid atheroscle-
rosis to be associated with cognitive decline over a 10-year
period [43,44]. These findings indicate a potential window
of opportunity for treatment of atherosclerosis which could
possibly delay or even stop the cognitive decline and
ultimately aid in the prevention of dementia.
When investigating the cognitive tests separately, in gen-
eral, we found small effects of calcification on the perfor-
mance on the tests. In agreement with others [45], we
found strong associations between atherosclerosis and the
LDST, which primarily assesses processing speed. Yet, it
was surprising that we did not find strong associations be-
tween atherosclerosis and executive function [43,45]. This
might be because our assessment of executive function
was not detailed or sensitive enough to assess small
changes. In our test battery there was namely only one test
that primarily investigated executive function; the WFT.
We only found an association of intracranial carotid artery
calcification with this test.
In conclusion, our findings further establish the role of
atherosclerosis in the etiology of dementia and cognitive
decline. This calls for studies evaluating whether interven-
tions targeted at reducing or stabilizing atherosclerosiswould
have a beneficial effect on the occurrence of dementia.Acknowledgments
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1. Systematic review: We searched PubMed for rela-
tionships between atherosclerosis and dementia or
cognition. We found multiple cross-sectional
studies showing associations of atherosclerosis
(restricted to one location) with cognition or de-
mentia. Longitudinal data are nevertheless scarce,
and it remains unclear whether atherosclerosis in
different vessel beds differentially affects cognition
and dementia.
2. Interpretation: We found that atherosclerosis, in
particular in the extracranial carotid arteries, is
related to a higher risk of dementia. We also found
that atherosclerosis plays an important role in the
process of cognitive deterioration, presumably
already years before the possible conversion to de-
mentia. This indicates a potential window of oppor-
tunity for treatment of atherosclerosis which could
delay or possibly stop the cognitive decline and ulti-
mately aid in preventing dementia.
3. Future directions: Important lines of future research
should focus on the predictive value of atheroscle-
rosis for dementia, and on the evaluation of treatment
strategies for atherosclerosis with regard to the
occurrence of dementia.
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Supplementary Table 2
Calcification in different vessel beds and cognitive decline after excluding persons who suffered a stroke (upper panel) or developed dementia (lower panel)
Global cognition MMSE
Difference in Z-score (95% CI) P Difference in points (95% CI) P
Per SD increase in:
Stroke excluded (n 5 90)
Coronary calcification 20.03 (20.05; 0.00) .06 20.11 (20.21;20.01) .03
Aortic arch calcification 20.02 (20.05; 0.00) .10 20.07 (20.17; 0.03) .15
Extracranial carotid calcification 20.02 (20.05; 0.01) .13 20.02 (20.12; 0.08) .69
Intracranial carotid calcification 20.04 (20.07; 20.02) ,.01 20.07 (20.16; 0.03) .19
Dementia excluded (n 5 42)
Coronary calcification 20.03 (20.06; 20.01) .02 20.13 (20.22; 20.03) ,.01
Aortic arch calcification 20.02 (20.05; 0.00) .09 20.09 (20.18; 0.00) .06
Extracranial carotid calcification 20.03 (20.05; 0.00) .05 20.03 (20.12; 0.06) .47
Intracranial carotid calcification 20.04 (20.06; 20.01) ,.01 20.09 (20.18; 0.00) .05
Abbreviations: CI, confidence interval; SD, standard deviation; n, number of cases.
NOTE. Adjusted for age, sex, time interval and level of education.
Supplementary Table 1
Vascular risk profiles across participants in the current study samples and the
total Rotterdam Study cohort
Variable
Rotterdam Study-
participants in present
analyses
Other Rotterdam
Study-participants*
N 5 2364 N 5 1847 N 5 3686
Women 52.3% 52.9% 63.1%
Age, yrs 69.4 (6.7) 68.4 (5.9) 75.3 (7.6)
Obesity 23.9% 23.8% 18.3%
BMI, kg/m2 27.7 (3.9) 27.7 (3.9) 27.5 (4.3)
Hypertension 73.7% 72.3% 79.0%
Systolic blood pressure,
mmHg
146.7 (20.1) 145.6 (19.1) 152.1 (22.1)
Diastolic blood pressure,
mmHg
80.3 (10.7) 80.1 (10.4) 79.3 (11.2)
Diabetes 11.2% 10.1% 14.9%
Serum glucose, mmol/L 5.7 (1.3) 5.7 (1.2) 6.0 (1.6)
Hypercholesterolemia 48.6% 49.1% 40.0%
Serum total cholesterol,
mmol/L
5.7 (1.0) 5.7 (1.0) 5.6 (1.0)
Low HDL cholesterol 10.6% 10.0% 7.4%
Serum HDL cholesterol,
mmol/L
1.4 (0.4) 1.4 (0.4) 1.5 (0.4)
Smoking, ever 67.5% 66.9% 65.2%
APOE ε4-carriers 25.6% 25.1% 25.6%
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein;
APOE, apolipoprotein E.
NOTE. Values are means (standard deviations) for continuous variables
and percentages for dichotomous variables.
*These are all other Rotterdam Study-participants that participated in the
follow-up visit [n 5 6050 (all), 2364 (current study) 5 3686].
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